Halozyme Therapeutics Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
All right. Hello, everyone, and welcome to day 2 of the 41st Annual Global Health Care Conference. By way of introduction, I'm Jack McNeil. I'm an associate on the U.S. SMID Biopharma and EU Biotech team, standing in for Graig Suvannavejh today.
And with us, we have Helen Torley, CEO of Halozyme Therapeutics.
So Helen, welcome back. I know you and Graig did this a year ago.
Questions & Answers
And I thought maybe we could talk about maybe what's changed for Halozyme in the past year. What are some of the major milestones you've hit and? What's top of mind today?
Yes. Thanks. And delighted to be back here. Thank you. Yes, 2019, I think people may be aware that in November, we got the readout of our PEGPH20 data. That was our
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
